By: Jeffrey Alan Hovden, Robins Kaplan LLP This article discusses strategies that counsel for brand-name and generic drug companies may employ in pharmaceutical patent litigation under the Drug Price Competition and Patent Term Restoration Act of 1984...

By: Matthew Bernstein , Perkins Coie LLP. THE MAJORITY OF PATENT CASES ARE BROUGHT BY non-practicing entities (NPEs), also called patent trolls or patent assertion entities (PAEs). These parties litigate or license their patents but have no real products...

By: Po Yi , Venable LLP. When your client plans to create new content or use existing third-party content in a new work, it must conduct a review to ensure that it is permitted to use the material. This review is known as rights clearance. UNAUTHORIZED...

By: Janet B. Linn , Tarter Krinsky & Drogin LLP This article addresses how counsel for a generic drug company should prepare for patent litigation under the Drug Price Competition and Patent Term Restoration Act of 1984, better known as the Hatch...

By: Rebecca K. Myers , Vandenberg & Feliu, LLP LEXIS PRACTICE ADVISOR RESEARCH PATH: Business & Commercial > Commercial Contracts > Confidentiality and Non-Disclosure Agreements > Practice Notes > Confidentiality Agreements CONFIDENTIALITY...